Q3 EPS Estimates for Journey Medical Increased by Analyst

Journey Medical Co. (NASDAQ:DERM) – Research analysts at Roth Capital lifted their Q3 2025 earnings estimates for Journey Medical in a report released on Thursday, March 27th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per share of $0.10 for the quarter, up from their previous estimate of $0.09. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2025 earnings at $0.16 EPS and FY2029 earnings at $5.83 EPS.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings results on Wednesday, March 26th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.30. The company had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.21 million. Journey Medical had a negative net margin of 31.74% and a negative return on equity of 132.10%.

Separately, Alliance Global Partners reaffirmed a “buy” rating on shares of Journey Medical in a research note on Thursday. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $9.67.

Journey Medical Price Performance

Shares of Journey Medical stock opened at $6.11 on Friday. The business’s fifty day moving average price is $5.09 and its 200 day moving average price is $5.16. Journey Medical has a twelve month low of $3.20 and a twelve month high of $6.89. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The stock has a market capitalization of $127.64 million, a P/E ratio of -6.50 and a beta of 0.97.

Institutional Trading of Journey Medical

A number of hedge funds have recently made changes to their positions in DERM. Tang Capital Management LLC purchased a new stake in Journey Medical during the 4th quarter worth $6,747,000. PVG Asset Management Corp boosted its position in Journey Medical by 5.7% in the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock valued at $947,000 after buying an additional 9,005 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Journey Medical by 13.5% during the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after acquiring an additional 12,882 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Journey Medical in the fourth quarter worth about $174,000. Finally, Kovitz Investment Group Partners LLC boosted its holdings in Journey Medical by 112.9% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock valued at $97,000 after purchasing an additional 13,105 shares during the last quarter. Hedge funds and other institutional investors own 7.25% of the company’s stock.

Insider Transactions at Journey Medical

In related news, CEO Claude Maraoui sold 23,508 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $5.19, for a total transaction of $122,006.52. Following the transaction, the chief executive officer now directly owns 2,139,922 shares of the company’s stock, valued at approximately $11,106,195.18. The trade was a 1.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders sold 105,831 shares of company stock valued at $536,622 over the last quarter. Company insiders own 13.16% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.